Anti-HLA-DR antibody [L243] (ab136320)
![Flow Cytometry - Anti-HLA-DR antibody [L243] (ab136320)](https://www.abcam.com/ps/products/136/ab136320/Images/ab136320-278895-anti-hla-dr-antibody-l243-flow-cytometry.jpg "Flow Cytometry - Anti-HLA-DR antibody [L243] (ab136320)")
Key features and details
- Mouse monoclonal [L243] to HLA-DR
- Suitable for: Flow Cyt
- Reacts with: Human
- Isotype: IgG2a
Related conjugates and formulations
Overview
-
Product name
Anti-HLA-DR antibody [L243]
See all HLA-DR primary antibodies -
Description
Mouse monoclonal [L243] to HLA-DR -
Host species
Mouse -
Specificity
ab136320 recognizes specifically HLA-DR molecules both peptide-loaded and empty. -
Tested applications
Suitable for: Flow Cytmore details -
Species reactivity
Reacts with: Human -
Immunogen
Tissue, cells or virus corresponding to Human HLA-DR. Human B lymphocytes.
-
Positive control
- Flow Cytometry: Human peripheral blood cells.
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.40
Preservative: 0.1% Sodium azide
Constituent: PBS -
Concentration information loading... -
Purity
Protein A purified -
Purification notes
Purified from cell culture supernatant by protein A affinity chromatography. Purity: > 95% (by SDS-PAGE). -
Clonality
Monoclonal -
Clone number
L243 -
Isotype
IgG2a -
Light chain type
kappa -
Research areas
Associated products
-
Alternative Versions
- PerCP/Cy5.5® Anti-HLA-DR antibody [L243] (ab157330)
- FITC Anti-HLA-DR antibody [L243] (ab210298)
- Alexa Fluor® 647 Anti-HLA-DR antibody [L243] (ab239277)
- PE/Cy5® Anti-HLA-DR antibody [L243] (ab239296)
- APC/Cy7® Anti-HLA-DR antibody [L243] (ab239308)
- PE/Cy7® Anti-HLA-DR antibody [L243] (ab239318)
- PE/DyLight™ 594 Anti-HLA-DR antibody [L243] (ab239320)
- redFluor™ 710 Anti-HLA-DR antibody [L243] (ab253079)
-
Compatible Secondaries
-
Conjugation kits
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab136320 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| Flow Cyt |
Use a concentration of 1 - 4 µg/ml.
ab170191 - Mouse monoclonal IgG2a, is suitable for use as an isotype control with this antibody.
|
| Notes |
|---|
|
Flow Cyt
Use a concentration of 1 - 4 µg/ml. ab170191 - Mouse monoclonal IgG2a, is suitable for use as an isotype control with this antibody.
|
Target
-
Function
Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form an heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal miroenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading. -
Sequence similarities
Belongs to the MHC class II family.
Contains 1 Ig-like C1-type (immunoglobulin-like) domain. -
Post-translational
modificationsUbiquitinated by MARCH1 or MARCH8 at Lys-244 leading to down-regulation of MHC class II. When associated with ubiquitination of the beta subunit of HLA-DR: HLA-DRB4 'Lys-254', the down-regulation of MHC class II may be highly effective. -
Cellular localization
Cell membrane. Endoplasmic reticulum membrane. Golgi apparatus > trans-Golgi network membrane. Endosome membrane. Lysosome membrane. Late endosome membrane. The MHC class II complex transits through a number of intracellular compartments in the endocytic pathway until it reaches the cell membrane for antigen presentation. - Information by UniProt
-
Database links
- Entrez Gene: 3122 Human
- Omim: 142860 Human
- SwissProt: P01903 Human
- Unigene: 520048 Human
-
Alternative names
- DASS-397D15.1 antibody
- DR alpha chain antibody
- DR alpha chain precursor antibody
see all
Images
-
Flow Cytometry - Anti-HLA-DR antibody [L243] (ab136320)
Flow Cytometry analysis of human peripheral blood cells labeling HLA DR with ab136320, followed by a Goat anti-mouse-APC secondary.
-
![Flow Cytometry - Anti-HLA-DR antibody [L243] (ab136320)](https://www.abcam.com/ps/products/136/ab136320/Images/ab136320-199446-anti-hla-dr-antibody-l243-flow-cytometry.jpg)
Flow Cytometry - Anti-HLA-DR antibody [L243] (ab136320)Human peripheral blood lymphocytes stained with ab136320 (red line). Human whole blood was processed using a modified protocol based on Chow et al, 2005 (PMID: 16080188).
In brief, human whole blood was fixed in 4% formaldehyde (methanol-free) for 10 minutes at 22°C. Red blood cells were then lyzed by the addition of Triton X-100 (final concentration - 0.1%) for 15 minutes at 37°C. For experimentation, cells were treated with 50% methanol (-20°C) for 15 minutes at 4°C. Cells were then incubated with the antibody (ab136320, 0.1μg/1x106 cells) for 30 minutes at 4°C. The secondary antibody used was Alexa Fluor® 488 goat anti-mouse IgG (H&L) (ab150113) at 1/2000 dilution for 30 minutes at 4°C. Isotype control antibody (black line) was mouse IgG2a [ICIGG2A] (ab91361, 0.1μg/1x106cells) used under the same conditions. Unlabeled sample (blue line) was also used as a control. Acquisition of >30,000 total events were collected using a solid-state 25mW red diode laser (635nm) and 675/30 bandpass filter. Gating strategy - peripheral blood lymphocytes.
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (10)
ab136320 has been referenced in 10 publications.
- Goodlet KJ et al. COVID-19 in a lung transplant recipient: Exploring the diagnostic role of circulating exosomes and the clinical impact of advanced immunosuppression. Transpl Infect Dis 23:e13480 (2021). PubMed: 32997881
- Li Q et al. Single-cell transcriptome profiling reveals vascular endothelial cell heterogeneity in human skin. Theranostics 11:6461-6476 (2021). PubMed: 33995668
- Sugawara E et al. Autophagy promotes citrullination of VIM (vimentin) and its interaction with major histocompatibility complex class II in synovial fibroblasts. Autophagy 16:946-955 (2020). PubMed: 31486697
- Bronge M et al. Myelin oligodendrocyte glycoprotein revisited-sensitive detection of MOG-specific T-cells in multiple sclerosis. J Autoimmun 102:38-49 (2019). PubMed: 31054941
- Shao S et al. IFN-? enhances cell-mediated cytotoxicity against keratinocytes via JAK2/STAT1 in lichen planus. Sci Transl Med 11:N/A (2019). PubMed: 31554739
- Zhou ZQ et al. Adipose extracellular matrix promotes skin wound healing by inducing the differentiation of adipose-derived stem cells into fibroblasts. Int J Mol Med 43:890-900 (2019). PubMed: 30535488
- Zheng SX et al. Feasibility analysis of treating severe intrauterine adhesions by transplanting menstrual blood-derived stem cells. Int J Mol Med 41:2201-2212 (2018). PubMed: 29393381
- Reichel FF et al. AAV8 Can Induce Innate and Adaptive Immune Response in the Primate Eye. Mol Ther 25:2648-2660 (2017). PubMed: 28970046
- Kant R et al. Homo-ß-amino acid containing MBP(85-99) analogs alleviate experimental autoimmune encephalomyelitis. Sci Rep 5:8205 (2015). PubMed: 25644378
- Laumbacher B et al. Activated monocytes prime naïve T cells against autologous cancer: vigorous cancer destruction in vitro and in vivo. Scand J Immunol 75:314-28 (2012). PubMed: 21995310